Cameron Turtle - 15 Feb 2024 Form 4 Insider Report for Spyre Therapeutics, Inc. (SYRE)

Role
Chief Executive Officer, Director
Signature
/s/ Heidy King-Jones, as Attorney-in-Fact
Issuer symbol
SYRE
Transactions as of
15 Feb 2024
Transactions value $
$3,928
Form type
4
Filing time
20 Feb 2024, 21:21:33 UTC
Previous filing
02 Feb 2024
Next filing
06 Sep 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SYRE Common Stock Award $3.93K +400 +0.05% $9.82* 747K 15 Feb 2024 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F2 Includes 493,558 shares of common stock that vest over an approximately three year period, subject to the continuing service of the Reporting Person on each vesting date.